Suma Krishnan

Cancer immunotherapy beyond immune checkpoint inhibitors

The re-emergence of natural products for drug discovery in the genomics era

Attention‐Deficit‐Hyperactivity Disorder: An Update

Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature

Natural products: An evolving role in future drug discovery

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Lisdexamfetamine

Hypersexual Disorder: A Proposed Diagnosis for DSM-V

Natural products to drugs: natural product-derived compounds in clinical trials

Diverse Engineered Heme Proteins Enable Stereodivergent Cyclopropanation of Unactivated Alkenes

A review on emerging contaminants in wastewaters and the environment: Current knowledge, understudied areas and recommendations for future monitoring

Drug-related hypertension and resistance to antihypertensive treatment

Discovery and resupply of pharmacologically active plant-derived natural products: A review

Natural products in drug discovery

Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder

Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

A Historical Overview of Natural Products in Drug Discovery

Natural product and natural product derived drugs in clinical trials

Amphetamine, past and present – a pharmacological and clinical perspective

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

The Traditional Medicine and Modern Medicine from Natural Products

2020 International Society of Hypertension Global Hypertension Practice Guidelines

Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU)

Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate

An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes

Relative Bioavailability of Lisdexamfetamine 70‐mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single‐Dose, Crossover Pharmacokinetic Study

Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder

Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

IMPS-03INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers

Improvements in Symptoms of Attention-Deficit/Hyperactivity Disorder in School-Aged Children with Lisdexamfetamine Dimesylate [LDX; NRP104] and Mixed Amphetamine Salts Extended-Release vs. Placebo

Abuse Liability Of Intravenous Lisdexamfetamine Dimesylate [LDX; NRP104]

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers